Is it Time for a Unified LDL-C Target? New Data Reopens the Debate in High-Risk Diabetes

Current ACC/AHA lipid management guidelines recommend a target LDL cholesterol below 70 mg/dL for high-risk diabetic patients in primary prevention and designate PCSK9 inhibitor therapy a Class IIb recommendation for those who do not meet that goal on maximally tolerated statin therapy—a notably lower level of endorsement than the Class I recommendations that govern lipid intensification in secondary prevention.¹ This discrepancy has persisted in part because, until recently, large randomized trial evidence supporting more aggressive LDL lowering in the primary prevention diabetes population was lacking.

New data from a secondary analysis of the VESALIUS-CV trial, presented at the American College of Cardiology's Annual Scientific Session in New Orleans, now provide some of the most compelling evidence to date that this gap should be narrowed. Nicholas Marston, MD, MPH, who presented the analysis, emphasized the degree to which current guidelines have not kept pace with the biological plausibility and emerging evidence base supporting aggressive LDL lowering in high-risk diabetic patients.² "We often think about historically diabetes as a CAD equivalent," he noted in the video above. "But if you look at the guidelines, we aren't as aggressive with treating LDL cholesterol levels in patients with diabetes as we are in those who are secondary prevention with coronary disease, especially if they've had an event."

In the VESALIUS-CV subgroup of patients with high-risk diabetes and no known significant atherosclerosis, evolocumab reduced 3-point MACE by 31% and cut cardiovascular death by 32%, with an all-cause mortality reduction of 24%. The drug lowered LDL to a median of approximately 44 mg/dL—a level that, in current practice, is typically achieved only in high-intensity secondary prevention scenarios. Whether these data will be sufficient to prompt a formal upward revision of PCSK9 inhibitor recommendations in the primary prevention diabetes population remains to be determined, but they represent a meaningful addition to a clinical evidence base that had long lacked a definitive large-scale trial.

Editors’ Note: Marston reports disclosures with Ionis, Lilly, Arrowhead, Janssen, Amgen, New Amsterdam, and others.

References:

1. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:3168-3209. doi:10.1016/j.jacc.2018.11.002
2. Marston NA, Bohula EA, Bhatia AK, et al. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial. JAMA. Published online March 28, 2026. doi:10.1001/jama.2026.3277